Brief: Kyverna's Kyv-101 Receives U.S. FDA Ind Clearance For Treatment-Refractory Stiff-Person Syndrome In Phase 2 Trial
20/06/2024 14:09
June 20 (Reuters) - Kyverna Therapeutics Inc KYTX.O :
* KYVERNA'S KYV-101 RECEIVES U.S. FDA IND CLEARANCE FOR
TREATMENT
OF PATIENTS WITH TREATMENT-REFRACTORY STIFF-PERSON SYNDROME IN
THE KYSA-8 PHASE 2 TRIAL
Source text for Eikon: ID:nPnb0GFkRa
Further company coverage: KYTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyverna Therapeutics
See all newsHealth Rounds: Appendix removal linked with lower colon cancer risk in study
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
U.S. STOCKS ON THE MOVE-Everpure, Dropbox, Darden Restaurants